A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.

被引：0
|
作者：
Baretti, Marina
Ding, Yingjun
Brancati, Madalena
Parkinson, Rose
Linden, Sheila
Hong, Kelvin
Liddell, Robert
Zheng, Lei
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16217
引用
收藏
页数：1
相关论文
共 4 条
  • [1] A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Owens, Helen
    Hankin, Amy
    Couvillon, Anna
    Houston, Nicole D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [2] A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+patients following adjuvant therapy for stage 2/3 triple negative breast cancer
    Isakoff, Steven J.
    Tolaney, Sara M.
    Tung, Nadine M.
    Adams, Sylvia
    Soliman, Hatem Hussein
    Brachtel, Elena F.
    Habin, Karleen R.
    Bauer, Louisa J.
    Ellisen, Leif W.
    Severgnini, Mariano
    Barry, William Thomas
    Peterkin, Doris
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
    Zhang, X.
    Cui, J.
    Quan, M.
    Zhang, T.
    Cao, D.
    Li, Z.
    Yang, D. T. C.
    Zhu, X.
    Chen, Y.
    Liang, P.
    Yao, L.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S934 - S935
  • [4] A phase II study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Lee, Sylvia
    Villaflor, Viktoriya
    Haigentz, Missack
    Karyampudi, Kumar
    Tanamly, Susie
    Suzuki, Sam
    Gorbatchevsky, Igor
    Fardis, Maria
    Villaruz, Liza
    CANCER RESEARCH, 2018, 78 (13)
1